When was Arbor Biotechnologies founded?

Arbor Biotechnologies was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Arbor Biotechnologies located?

Arbor Biotechnologies is headquartered in Cambridge, United States.

How many employees does Arbor Biotechnologies have?

As of Aug 31, 2026, the latest employee count at Arbor Biotechnologies is 102.

Is Arbor Biotechnologies a funded company?

Arbor Biotechnologies is a funded company, having raised a total of $304M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 02, 2017.

When was the latest funding round of Arbor Biotechnologies?

Arbor Biotechnologies' latest funding was a $***** Series C round on Oct 30, 2025, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.25B in funding in 2026 to date.

Where does Arbor Biotechnologies rank among its competitors?

Arbor Biotechnologies ranks 2nd amongst 62 active competitors, of which 17 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Eclipse Bio, which secured $4.91M in Nov, 2025.

Who are the top competitors of Arbor Biotechnologies?

Arbor Biotechnologies' top competitors include Illumina, MGI and Eclipse Bio. Among them, Eclipse Bio secured the most recent funding round in November, 2025.

Arbor Biotechnologies - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of genomic technologies and drug discovery platform. This platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening for enabling the discovery of proteins. The company has also identified a new CRISPR enzyme using its discovery platform.

Website: arbor.bio
Social
Email ID: *****@arbor.bio

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Series C

Total Funding

$304M in 4 rounds

Latest Funding Round

Series C, Oct 30, 2025, $*****

Investors

TCG Crossover & 28 more

Ranked

2^nd among 62 active competitors

Employee Count

102 as on Aug 31, 2026

Investment & Acquisitions

Serendipity Biosciences

Similar Companies

Illumina & 68 more

View Arbor Biotechnologies' full profile

Arbor Biotechnologies is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Arbor Biotechnologies, Inc. CIN: 6103398 , United States, Active		-	117 (As on Dec 31, 2022)	-

Arbor Biotechnologies has raised a total funding of $304M over 4 rounds. Its first funding round was on Aug 02, 2017. Its latest funding round was a Series C round on Oct 30, 2025 for $*****. 1 investor participated in its latest round. Arbor Biotechnologies has 27 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Arbor Biotechnologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 30, 2025	2166674	Series C	7035523	8039729	1012820	5862179
Mar 18, 2025	2764423	Series C	8717530	3200961	3680589	Vertex Pharmaceuticals & 7 more
Nov 09, 2021	4586514	Series B	2318450	3530182	Temasek & 2 more	Arch Venture Partners & 15 more

Access funding benchmarks and valuations. Sign up today!

View details of Arbor Biotechnologies's funding rounds and investors

The founders of Arbor Biotechnologies is Feng Zhang.

Here are the details of Arbor Biotechnologies' key team members:

Feng Zhang: Co-Founder of Arbor Biotechnologies and founder of 1 other company. They serve on the board of 1 company.

Arbor Biotechnologies' Board of Directors

Arbor Biotechnologies's board has 16 active members. David R Walt, Chen Yu, Keith Crandell, Annie Hazlehurst, Feng Zhang, John Murphy, Mark Angelino, David C., Kelly Morgan, PAUL MEISTER, DAVID R. WALT, DAVID ARTHUR SCOTT, Devyn Smith, RAMI HARAWI, PAM STETKIEWICZ and WINSTON XIA YAN are independent board members.

Here is the list of Arbor Biotechnologies' board of directors:

Name	Type	Representing	Status	Duration
David R Walt	Independent board member	-	Current	4y 10m
wmcnnuk	Independent board member	-	Current	8y 9m
tjvfaxw	Independent board member	-	Current	9y 1m
{fs{fjm	Independent board member	-	Current	5y 2m
lzyrabb	Independent board member	-	Current	1y 8m
pfynjtz	Independent board member	-	Current	2y 1m
h{aktib	Independent board member	-	Current	1y 9m
ydbtlgb	Independent board member	-	Current	3y 3m
pmgbtzw	Independent board member	-	Current	9y 4m
urtinil	Independent board member	-	Current	4y 8m
{qcpto{	Independent board member	-	Current	8y 2m
kwylvwb	Independent board member	-	Current	8y 9m
zfomtdb	Independent board member	-	Current	1y 2m
hulmmzs	Independent board member	-	Current	5y 1m
btj{fth	Independent board member	-	Current	7y 5m
ewqwsqj	Independent board member	-	Current	3y 9m

View details of Arbor Biotechnologies's Founder profiles and Board Members

Arbor Biotechnologies' employee count trend

Arbor Biotechnologies has 102 employees as of Aug 26. Here is Arbor Biotechnologies's employee count trend over the years:

Employee count trend for Arbor Biotechnologies

Uncover Arbor Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Arbor Biotechnologies include Illumina, MGI and Eclipse Bio. Here is the list of Top 10 competitors of Arbor Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Illumina 1993, San Diego (United States), Public	Developer of technologies for analysis of genetic variation and function	$28M	Chevron Technology Ventures, Dow Chemical Company ... & 32 others	71/100
2nd	Arbor Biotechnologies 2016, Cambridge (United States), Series C	Provider of genomic technologies and drug discovery platform	$304M	T. Rowe Price, ArrowMark Partners & 27 others	64/100
3rd	MGI 2016, Shenzhen (China), Series B	Provider of gene sequencing instruments, reagents, equipment, and related products	$1B	Guotai Junan Securities, CoStone Capital ... & 13 others	63/100
4th	Eclipse Bio 2017, San Diego (United States), Series A	Developer of cell-free immunoassay	$18.9M	Alexandria, IGlobe Partners & 2 others	61/100
5th	Epredia 2019, United Kingdom, Unfunded	Developer of in-vitro diagnostic test for cancer	-	-	55/100
6th	Factor Bioscience 2011, Cambridge (United States), Seed	Developer of genomic technologies to treat disease and improve health	$1M	Military Health, SBIR & 1 others	55/100
7th	Octant 2017, Los Angeles (United States), Series B	Provider of human cell interaction platform for drug discovery	$115M	Catalio Capital Management, Andreessen Horowitz ... & 15 others	51/100
8th	Singleron 2018, Hagen (Germany), Series B	Developer of single-cell multi-omics platform for clinical research and molecular diagnosis	$84.5M	Yuanhe Holdings, Frees Fund & 13 others	49/100
9th	Genechem 2002, Shanghai (China), Series C	Products and services in molecular biology	$56.4M	Free Trade Zone Fund, Humanwell Healthcare ... & 2 others	46/100
10th	Nonacus 2015, Birmingham (United Kingdom), Unfunded	Provider of technology and services for genomic healthcare	-	-	45/100